Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment;Enquête observationnelle sur les conditions d'utilisation des bithérapies dans le traitement de l'hypertonie oculaire ou du glaucome à angle ouvert en France

Journal Francais d'Ophtalmologie

Volumn 29, Issue 2, 2006, Pages 164-168

  Bron, A ^a,e   Nordmann, J P ^b   Rouland, J F ^c   Baudouin, C ^b   Sartral, M ^d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d PFIZER INC   (United States)

^e HÔPITAL DU BOCAGE   (France)

Author keywords

Add on therapy; Glaucoma; Ocular hypertension

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATION; OPEN ANGLE GLAUCOMA; OPHTHALMOLOGY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRE; SCLEROTOMY; TRABECULOPLASTY; TRABECULOTOMY;

EID: 33644823053     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(06)73765-2     Document Type: Article

References (22)

1. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology, 2001;108:1943-53.
2. Heijl A, Leske C, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol, 2002;120:1268-79.
3. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol, 2000;130:429-40.
4. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol, 1998;126:487-97.
5. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. A Randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol, 2002;120:701-3.
6. Naacke H, Baudouin C. Le patient glaucomateux et son traitement : qu'en est-il réellement ? J Fr Ophtalmol, 1999;22:99-101.
7. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol, 1998;236:811-21.
8. Rouland JF, Le Pen C. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol, 2003;13(Suppl 4):S5-20.
9. Grehn F. World health problem of glaucoma. J Glaucoma, 2001;10(Supl1):S2-4.
10. Realini T, Fechtner RD. 56000 ways to treat glaucoma. Ophthalmology, 2002;109:1955-6.
11. Gandolfi SA. Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma. Invest Ophthalmol Vis Sci, 1990;31:354-8.
12. Bengtsson B, Heijl A. Lack of long-term drift in timolol's effectiveness in patients with ocular hypertension. Invest Ophthalmol Vis Sci, 2001;42:2839-42.
13. Terminology and guidelines for glaucoma. European Glaucoma Society. Second edition, Edit Dogma, Savona, 2003.
14. Bron A, Nordmann JP, Baudouin C, Rouland JF, Kadi A, Sartral M. Glaucome et hypertonie oculaire : importance de la pression intraoculaire cible dans la prise en charge thérapeutique en France. J Fr Ophtalmol, 2003;26:895-903.
15. Baudouin C, Bechetoille A, Bron A, Denis P, Nordmann JP, Renard JP et al. Intérêt de la mesure de la qualité de vie (QDV) et de l'observance thérapeutique chez les patients atteints de glaucome chronique à angle ouvert. J Fr Ophtalmol, 2000;23:1057-64.
16. Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol, 2004;88:199-203.
17. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 1994;101:454-60.
18. Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, Bechetoille A. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology, 1999;106:556-63.
19. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol, 1990;108:1543-8.
20. Roth HP, Caron HS. Accuracy of doctor's estimates and patients's statements on adherence to a drug regimen. Clin Pharmacol Ther, 1978;23:361-70.
21. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol, 1986;101:515-23.
22. Ashburn FS, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol, 1980;24:237-48.